Otsuka has high hopes for its ‘drug creation engine’ acquisitionOtsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug Share XOtsuka has high hopes for its ‘drug creation engine’ acquisitionhttps://pharmaphorum.com/news/otsuka-biotech-visterra-hierotope/
